AG
ITCI

Aperio Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Aperio Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$862K Sell
27,113
-45
-0.2% -$1.18K ﹤0.01% 1679
2020
Q3 		$697K Buy
27,158
+2,876
+12% +$65.6K ﹤0.01% 1629
2020
Q2 		$624K Buy
24,282
+666
+3% +$13.5K ﹤0.01% 1663
2020
Q1 		$363K Buy
23,616
+132
+0.6% +$2.87K ﹤0.01% 1814
2019
Q4 		$806K Buy
23,484
+7,192
+44% +$86.3K ﹤0.01% 1553
2019
Q3 		$121K Sell
16,292
-914
-5% -$8.76K ﹤0.01% 2229
2019
Q2 		$223K Buy
17,206
+2,367
+16% +$30.4K ﹤0.01% 2138
2019
Q1 		$181K Buy
+14,839
New +$190K ﹤0.01% 2180

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Aperio Group's ITCI Position: Q4 2020 in Review

Aperio Group reduced its Intra-Cellular Therapies Inc. (ITCI) stake by 0.17% in Q4 2020, selling an estimated $1.18K and leaving 27,113 shares worth $862K. The position accounts for ﹤0.01% of the portfolio, ranked #1679.

Aperio Group first reported a position in ITCI in Q1 2019 and has held it in 8 quarters since. 178 funds tracked by Wall St. Rank hold ITCI as of Q4 2020.

  • Aperio Group held 27,113 shares of Intra-Cellular Therapies Inc. worth $862K as of Q4 2020.
  • Aperio Group sold 45 Intra-Cellular Therapies Inc. shares in Q4 2020, an estimated $1.18K.
  • Intra-Cellular Therapies Inc. made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1679 holding.
  • Aperio Group first reported a position in Intra-Cellular Therapies Inc. in Q1 2019 and has held it in 8 quarters since.
  • 178 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.